Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Bristol-Myers Squibb Co — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.82, while Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | BMY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $65.89 |
52-Week Low | $43.88 | $42.60 |
Market Cap | — | $129.94B |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ (Global X Artificial Intelligence & Technology ETF) trades at $63.77, up 0.41% with strong bullish momentum. Technical indicators show the stock above key moving averages with RSI suggesting mild overbought conditions. Recent news highlights AIQ's outperformance versus the Nasdaq, gaining 25% while attracting attention as a diversified AI play beyond semiconductor stocks. The ETF's systematic rebalancing approach positions it well for the evolving AI investment landscape.
AIQ offers exposure to the growing artificial intelligence sector with reduced single-stock risk. Key catalysts include upcoming AI company IPOs and federal quantum computing funding. Risks include thematic ETF volatility and premium fees compared to broader indices. The stock's proximity to resistance levels near $64 suggests potential near-term consolidation before further upside.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
